IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 75.001
AS - Asia 9.073
EU - Europa 6.594
SA - Sud America 1.507
Continente sconosciuto - Info sul continente non disponibili 1.478
AF - Africa 146
OC - Oceania 31
Totale 93.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 74.682
SG - Singapore 4.008
IT - Italia 1.709
CN - Cina 1.611
BR - Brasile 1.247
RU - Federazione Russa 1.092
HK - Hong Kong 995
IE - Irlanda 771
VN - Vietnam 700
UA - Ucraina 682
DE - Germania 640
KR - Corea 502
BD - Bangladesh 460
FR - Francia 433
GB - Regno Unito 364
FI - Finlandia 291
JP - Giappone 251
CA - Canada 166
IN - India 144
NL - Olanda 133
SE - Svezia 113
PL - Polonia 98
AR - Argentina 92
AT - Austria 73
ID - Indonesia 71
ES - Italia 62
MX - Messico 62
ZA - Sudafrica 48
CO - Colombia 40
IQ - Iraq 38
TR - Turchia 34
EC - Ecuador 31
AU - Australia 30
PK - Pakistan 24
PY - Paraguay 24
VE - Venezuela 24
PH - Filippine 23
UZ - Uzbekistan 23
BE - Belgio 22
IR - Iran 22
EG - Egitto 21
MA - Marocco 21
JM - Giamaica 20
CR - Costa Rica 19
EU - Europa 19
CL - Cile 18
KZ - Kazakistan 17
LT - Lituania 17
MY - Malesia 15
SA - Arabia Saudita 15
JO - Giordania 14
TH - Thailandia 14
AE - Emirati Arabi Uniti 13
KE - Kenya 13
PE - Perù 13
DZ - Algeria 12
NP - Nepal 12
UY - Uruguay 12
CH - Svizzera 11
CZ - Repubblica Ceca 10
AZ - Azerbaigian 9
TN - Tunisia 9
TT - Trinidad e Tobago 9
DO - Repubblica Dominicana 8
RO - Romania 8
TW - Taiwan 8
AL - Albania 7
BB - Barbados 7
GT - Guatemala 7
IL - Israele 7
GR - Grecia 6
HR - Croazia 6
KG - Kirghizistan 6
BG - Bulgaria 5
BO - Bolivia 5
HN - Honduras 5
HU - Ungheria 5
PS - Palestinian Territory 5
PT - Portogallo 5
SN - Senegal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BN - Brunei Darussalam 4
GE - Georgia 4
MD - Moldavia 4
MK - Macedonia 4
PR - Porto Rico 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
BY - Bielorussia 3
GD - Grenada 3
LU - Lussemburgo 3
NG - Nigeria 3
OM - Oman 3
QA - Qatar 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
Totale 92.337
Salva come PNG Salva come JPEG
Città #
Houston 22.133
Woodbridge 18.291
Wilmington 16.093
Fairfield 2.305
Singapore 2.204
Ashburn 1.589
Ann Arbor 1.486
San Jose 1.077
Hong Kong 980
Seattle 915
Cambridge 834
Chandler 819
Dublin 710
Jacksonville 594
Dearborn 574
Beijing 573
Council Bluffs 530
Medford 527
Rome 489
New York 397
Santa Clara 394
Dallas 348
The Dalles 345
Los Angeles 277
Lawrence 253
Ho Chi Minh City 237
Lauterbourg 228
Tokyo 221
Moscow 176
Buffalo 158
Milan 152
Hanoi 147
Hangzhou 133
San Diego 121
São Paulo 112
Menlo Park 102
London 92
Helsinki 91
Chicago 74
North Bergen 71
Nuremberg 70
Orem 67
Redondo Beach 59
Boardman 58
Munich 53
Creede 52
Center 51
Atlanta 50
Phoenix 49
Brooklyn 46
Seoul 44
Toronto 44
Jakarta 43
Warsaw 42
Norwalk 41
Engelhard 40
Shanghai 40
Denver 39
Frankfurt am Main 39
Kraków 39
Da Nang 34
Rio de Janeiro 34
Chennai 33
Florence 33
Guangzhou 33
Zhengzhou 33
Montreal 32
Nanjing 32
Naples 32
Vienna 32
Hefei 31
Monte Vista 31
Bologna 28
Mountain View 28
Stockholm 27
Verona 27
Hackensack 26
Haiphong 26
Washington 26
Belo Horizonte 25
San Francisco 25
Baghdad 24
Detroit 24
Redwood City 24
Amsterdam 23
Brasília 23
Columbus 23
Lappeenranta 23
Johannesburg 22
Philadelphia 22
Bari 20
Curitiba 20
Guarulhos 19
Brussels 18
Dhaka 18
Kunming 18
Manchester 18
Milwaukee 18
Pune 18
Charlotte 17
Totale 78.838
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.385
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.676
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.644
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.264
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.190
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 550
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 514
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 508
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 502
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 479
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 472
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 471
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 471
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 471
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 466
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 462
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 462
Clonal evolution in therapy-related neoplasms 462
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 460
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 459
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 458
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 452
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 451
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 451
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 451
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 448
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 448
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 445
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 444
Panobinostat for the treatment of acute myelogenous leukemia 442
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 442
Therapy related leukemias: susceptibility, prevention and treatment 440
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 439
New treatments for myelodysplastic syndromes 439
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 435
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 435
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 434
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 434
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 432
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 432
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 430
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 429
Small lymphocytic lymphoma in a patient with Fabry disease 429
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 429
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 426
Why methylation is not a marker predictive of response to hypomethylating agents 426
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 426
Prevalence of obesity in young adults with acute lymphoblastic leukemia 424
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 423
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 423
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 422
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 422
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 421
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 420
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 420
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 419
Hepato-splenic mycotic abscesses in patients with acute leukemia 419
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 416
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 416
Mobilization and selection of CD34+ cells 416
Epigenetic changes in therapy-related MDS/AML 416
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 416
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 415
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 414
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 412
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 411
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 409
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia 409
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 408
Incidence and susceptibility to therapy-related myeloid neoplasms 408
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 408
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 408
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 407
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 407
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 407
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 407
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 406
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 406
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 406
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 405
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 405
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 405
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 405
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 403
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 402
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 402
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 402
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 401
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 401
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 400
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial 400
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 399
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 398
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 397
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 396
The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia 396
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 395
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 395
Treatment of low-blast count AML using hypomethylating agents 395
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 393
Totale 48.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 235.054
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 235.054
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.369 0 293 127 61 78 198 129 148 178 143 268 746
2022/20232.760 339 173 135 270 180 696 484 119 205 20 77 62
2023/20241.297 126 37 149 56 124 346 67 33 51 40 30 238
2024/20256.762 179 1.438 783 446 133 355 681 337 799 568 568 475
2025/202611.867 916 611 1.522 879 966 366 1.439 1.353 1.359 1.041 785 630
2026/20271.416 748 668 0 0 0 0 0 0 0 0 0 0
Totale 93.830